A Phase Ib/II, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of LG00034053 Administered by Intra-articular Injection in Patients With Knee Osteoarthritis
Latest Information Update: 08 May 2024
At a glance
- Drugs LG 00034053 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors LG Chem
Most Recent Events
- 02 May 2024 Status changed from active, no longer recruiting to completed.
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2023 Planned End Date changed from 30 Dec 2023 to 30 Nov 2024.